BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 17242926)

  • 1. Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue vaccine.
    Suckow MA; Rosen ED; Wolter WR; Sailes V; Jeffrey R; Tenniswood M
    Cancer Immunol Immunother; 2007 Aug; 56(8):1275-83. PubMed ID: 17242926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of prostate cancer metastasis by administration of a tissue vaccine.
    Suckow MA; Wolter WR; Sailes VT
    Clin Exp Metastasis; 2008; 25(8):913-8. PubMed ID: 18821060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization with a tissue vaccine enhances the effect of irradiation on prostate tumors.
    Suckow MA; Wheeler J; Wolter WR; Sailes V; Yan M
    In Vivo; 2008; 22(2):171-7. PubMed ID: 18468400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of an extracellular matrix material as a vaccine carrier and adjuvant.
    Suckow MA; Hall P; Wolter W; Sailes V; Hiles MC
    Anticancer Res; 2008; 28(5A):2529-34. PubMed ID: 19035274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy.
    Rountree RB; Mandl SJ; Nachtwey JM; Dalpozzo K; Do L; Lombardo JR; Schoonmaker PL; Brinkmann K; Dirmeier U; Laus R; Delcayre A
    Cancer Res; 2011 Aug; 71(15):5235-44. PubMed ID: 21670078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF.
    Lewis JD; Sullivan LA; Byrne JA; de Riese W; Bright RK
    Cancer Immunol Immunother; 2009 Aug; 58(8):1337-49. PubMed ID: 19169682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo.
    Wu YG; Wu GZ; Wang L; Zhang YY; Li Z; Li DC
    Med Oncol; 2010 Sep; 27(3):736-42. PubMed ID: 19669608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer.
    Suzuki K; Nakazato H; Matsui H; Hasumi M; Shibata Y; Ito K; Fukabori Y; Kurokawa K; Yamanaka H
    J Leukoc Biol; 2001 Apr; 69(4):531-7. PubMed ID: 11310838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination against prostate cancer using a live tissue factor deficient cell line in Lobund-Wistar rats.
    Heinrich JE; Pollard M; Wolter WA; Liang Z; Song H; Rosen ED; Suckow MA
    Cancer Immunol Immunother; 2007 May; 56(5):725-30. PubMed ID: 16953436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor efficacy of interferon-γ-modified exosomal vaccine in prostate cancer.
    Shi X; Sun J; Li H; Lin H; Xie W; Li J; Tan W
    Prostate; 2020 Aug; 80(11):811-823. PubMed ID: 32427375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity.
    Dredge K; Marriott JB; Todryk SM; Muller GW; Chen R; Stirling DI; Dalgleish AG
    J Immunol; 2002 May; 168(10):4914-9. PubMed ID: 11994441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of de novo prostate cancer by immunization with tumor-derived vaccines.
    Suckow MA; Wolter WR; Pollard M
    Cancer Immunol Immunother; 2005 Jun; 54(6):571-6. PubMed ID: 15685450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic whole-tumour cell vaccination in the rat model of prostate cancer.
    Hrouda D; Todryk SM; Perry MJ; Souberbielle BE; Kayaga J; Kirby RS; Dalgleish AG
    BJU Int; 2000 Oct; 86(6):742-8. PubMed ID: 11069388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colon cancer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7.1 and interleukin-2 induce antitumor response in syngeneic mice.
    Sivanandham M; Shaw P; Bernik SF; Paoletti E; Wallack MK
    Cancer Immunol Immunother; 1998 Jul; 46(5):261-7. PubMed ID: 9690454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables.
    Michael A; Ball G; Quatan N; Wushishi F; Russell N; Whelan J; Chakraborty P; Leader D; Whelan M; Pandha H
    Clin Cancer Res; 2005 Jun; 11(12):4469-78. PubMed ID: 15958632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer.
    Cappuccini F; Stribbling S; Pollock E; Hill AV; Redchenko I
    Cancer Immunol Immunother; 2016 Jun; 65(6):701-13. PubMed ID: 27052571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines.
    Dunussi-Joannopoulos K; Dranoff G; Weinstein HJ; Ferrara JL; Bierer BE; Croop JM
    Blood; 1998 Jan; 91(1):222-30. PubMed ID: 9414288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer.
    Klyushnenkova EN; Kouiavskaia DV; Parkins CJ; Caposio P; Botto S; Alexander RB; Jarvis MA
    J Immunother; 2012 Jun; 35(5):390-9. PubMed ID: 22576344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.